Clinical Trial Update: Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vemurafenib and cobimetinib for BRAF V600E mutation-positive craniopharyngioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma
• Papillary Craniopharyngioma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: BRAF V600E Mutation Present, Papillary Craniopharyngioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING